Skip to Main content Skip to Navigation
Journal articles

Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse

Abstract : It is widely assumed that the upcoming therapeutics for Alzheimer's disease will require to act on more than one target to be effective. We investigated here whether a combination of the nicotinic receptor allosteric modulator/cholinesterase inhibitor galantamine can act synergistically with the type 4 serotonin receptor (5-HT4R) partial agonist, RS-67333, to counterbalance deficits in short- and long-term memory. To select sub-efficacious doses of both drugs, dose-response studies were first performed on the scopolamine-induced deficits of spontaneous alternation in the Y-maze task and of acquisition and retrieval processes in a passive avoidance task.
Complete list of metadatas

https://hal-normandie-univ.archives-ouvertes.fr/hal-02135214
Contributor : François Dauphin <>
Submitted on : Tuesday, May 21, 2019 - 10:09:37 AM
Last modification on : Thursday, January 9, 2020 - 12:42:02 PM

Identifiers

Collections

Citation

Thomas Freret, Véronique Lelong-Boulouard, Pierre Lecouflet, Katia Hamidouche, François Dauphin, et al.. Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse. Psychopharmacology, Springer Verlag, 2017, 234 (15), pp.2365-2374. ⟨10.1007/s00213-017-4664-z⟩. ⟨hal-02135214⟩

Share

Metrics

Record views

58